Clinical Trial Update: A Study of RC48-ADC for the Treatment of HER2-expressing Gynecological Malignancies [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for RC48-ADC in HER2-expressing gynecological malignancies.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gynecological Malignancy

Drugs mentioned

• RC48-ADC (Disitamab Vedotin)

Snippet

Sponsor: RemeGen Co., Ltd. | Conditions: Gynecological Malignancy | Phase 2 | Status: UNKNOWN